RWA
REGN icon

Redmont Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Redmont Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7
Closed -$3.67K – 310
2025
Q2 		$3.67K Buy
+7
New +$3.91K 0.01% 268
2024
Q4 		– Sell
-7
Closed -$7.36K – 247
2024
Q3 		$7.36K Hold
7
– – 0.01% 207
2024
Q2 		$7.36K Hold
7
– – 0.01% 210
2024
Q1 		$6.74K Buy
+7
New +$6.66K 0.01% 220

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmont Wealth Advisors's REGN Position: Q3 2025 in Review

Redmont Wealth Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 7 shares — an estimated $3.67K sold.

Redmont Wealth Advisors first reported a position in REGN in Q1 2024 and held it in 4 quarters. The position peaked at $7.36K in Q3 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

  • Redmont Wealth Advisors reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Redmont Wealth Advisors sold 7 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $3.67K.
  • Redmont Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Redmont Wealth Advisors's Regeneron Pharmaceuticals position peaked at $7.36K in Q3 2024.
  • 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Redmont Wealth Advisors's 13F filing for Q3 2025, filed 7 Nov 2025.